Dietary Strategies and Nutritional Management in Patients Receiving GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials
Diabetes, Obesity and Metabolism · 2026-07 · 28 (7) · 5492-5507
DOI: 10.1111/dom.70779 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 27.04.2026. Verfasst von Rayanne Santos de Paulo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition and Health, Universidade Federal de Viçosa, Viçosa, Brazil. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Obesity, Gastric Inhibitory Polypeptide. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Abstract (Originalsprache)
Background
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and dual GIP/GLP‐1 RAs are widely used to manage obesity, prediabetes and type 2 diabetes, typically in combination with lifestyle interventions. Their nutritional implications, however, remain unclear. This systematic review summarised evidence from randomised clinical trials investigating dietary strategies and nutritional management in individuals treated with these medications.
Methods
The review followed PRISMA guidelines and was registered in PROSPERO (CRD420251181076). Searches were conducted in PubMed, Embase, Scopus and Web of Science. Eligible studies were randomised clinical trials evaluating adults receiving GLP‐1 or dual GIP/GLP‐1 agonists in conjunction with lifestyle or dietary guidance. Outcomes included gastrointestinal symptoms, muscle and bone health and nutritional adequacy.
Results
Sixteen trials involving 7096 participants were included. GLP‐1 and dual agonists consistently increased gastrointestinal symptoms such as nausea, diarrhoea, constipation and vomiting. These effects were often dose‐related and occurred despite background lifestyle or dietary interventions. Lean mass was generally preserved, with reductions proportional to overall weight loss. No study directly assessed bone health, and none reported clinically relevant nutritional deficiencies. Most trials presented a low risk of bias.
Conclusion
GLP‐1 and dual GIP/GLP‐1 agonists frequently cause gastrointestinal discomfort but tend to preserve lean mass during weight loss when used alongside lifestyle interventions. Although dietary guidance is commonly provided, evidence on optimal nutritional approaches remains limited. Further trials are needed to clarify protein requirements, assess musculoskeletal outcomes and establish evidence‐based dietary recommendations to support combined treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nutrition and Health, Universidade Federal de Viçosa, Viçosa, Brazil.
ORCID-Profile: Rayanne Santos de Paulo, Josefina Bressan
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
de Paulo, R. S., Bonifácio, D. B., de Carvalho, M. H. L., & Bressan, J. (2026). Dietary Strategies and Nutritional Management in Patients Receiving GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials. Diabetes, Obesity and Metabolism, 28(7), 5492-5507. https://doi.org/10.1111/dom.70779
Vancouver
de Paulo RS, Bonifácio DB, de Carvalho MHL, Bressan J. Dietary Strategies and Nutritional Management in Patients Receiving GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials. Diabetes, Obesity and Metabolism. 2026;28(7):5492-5507. doi:10.1111/dom.70779
BibTeX
@article{dePaulo2026,
author = {de Paulo, Rayanne Santos and Bonifácio, Dandara Baia and de Carvalho, Matheus Henrique Lana and Bressan, Josefina},
title = {Dietary Strategies and Nutritional Management in Patients Receiving GLP ‐1 and Dual GIP / GLP ‐1 Receptor Agonists as Adjuncts to Lifestyle Interventions: A Systematic Review of Randomised Clinical Trials},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
volume = {28},
number = {7},
pages = {5492--5507},
doi = {10.1111/dom.70779}
}
EUVIMED